Article

Video blog: HER2-targeted agents

Author(s):

Debu Tripathy

Dr. Debu Tripathy explains the HER2 pathway's involvement in breast cancer and how new investigational drugs, including pertuzumab and TDM1, as well as combinations of new and approved drugs are targeting this pathway.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Related Content
CHRISTIE GRIFFIN-JONES, MBA-HCM, B.S.N., RN, CPHQ, CRRN, and MIKELA PETTIGREW, B.S.N., RN, OCN
April 25th 2025

Commitment to Patients Is Driven by a Lasting Promise

Christie Griffin-Jones, MBA-HCM, B.S.N., RN, CPHQ, CRRN
Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Illustration of georgia.
April 25th 2025

A Digital Detox for the Soul with Lynch Syndrome

Georgia Hurst
Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of neck.
April 25th 2025

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

Alex Biese
In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.
picture of lungs
April 25th 2025

ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

Ryan Scott
Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.